drugset / Trial / NCT01870297
A Study of LY3025876 in Participants With Diabetes
RandomizedParallel-groupDouble-blindBasic science
Summary
The main purpose of this study is to assess the safety and tolerability of LY3025876 given alone (Part A) and in combination with liraglutide (Part B) in participants with type 2 diabetes mellitus (T2DM).
Timeline
- Start
- 2013-06
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY3025876 | Unknown | 0.5 mg | Subcutaneous |
| Subject | LY3025876 | Unknown | 1.5 mg | Subcutaneous |
| Subject | LY3025876 | Unknown | 5 mg | Subcutaneous |
| Subject | LY3025876 | Unknown | 15 mg | Subcutaneous |
| Background | Liraglutide | Peptide | 1.8 mg | Subcutaneous |